BOSTON and LAUSANNE,
Switzerland, May 5, 2022 /PRNewswire/ -- SOPHiA GENETICS
(Nasdaq: SOPH), a leader in data-driven medicine, today
announced the nomination of Jean-Michel Cosséry to its Board of
Directors. The Board of Directors will propose the appointment of
Mr. Cosséry as a member of the Board of Directors and a member of
the Compensation Committee to the Annual General Meeting of
Shareholders of SOPHiA GENETICS SA, to convene on June 15, 2022.
"A thoughtful and passionate leader, Jean-Michel offers a
tremendous diversity of experiences across functions, companies,
and the industries we serve and collaborate with every day," said
Jurgi Camblong, co-founder and CEO of SOPHiA GENETICS. "We are
pleased to welcome him to SOPHiA's Board of Directors and look
forward to benefiting from his leadership expertise to help
accelerate our growth strategy across oncology and biopharma."
Mr. Cosséry brings to the board more than 25 years of industry
experience in research, marketing and commercial operations for
med-tech and pharmaceuticals, having served in numerous management
positions at Novartis and Serono before joining GE Healthcare as
Chief Marketing Officer and Vice President, Global Marketing. He
most recently served as Vice President, North American Oncology and
Managing Director, Northern Europe
at Eli Lilly.
"SOPHiA GENETICS is a leader and innovator in a field which has
the potential to change the way healthcare is delivered, an
industry with an incredible growth opportunity ahead," said
Jean-Michel Cosséry. "It's an honor to join the company's Board of
Directors, and I am excited to collaborate with such a fantastic
team in guiding the continued success of SOPHiA's mission-driven
approach to enable and enhance health outcomes worldwide."
Mr. Cosséry currently serves on the Board of Directors of Malin,
a publicly listed Irish investment company; Exact Therapeutics, a
publicly listed Norwegian biotech company; Diurnal Plc, a publicly
listed UK specialty pharma; and Eracal Therapeutics, an early-stage
privately owned Swiss biotech company. He was previously a Board
Member of ABPI in the UK; Chairman of the Board of the American
Pharmaceutical Group; Board Member of Immunocore in the UK until
its IPO; and Board Member of Kymabin in the UK until its sale to
Sanofi.
Mr. Cosséry holds an MBA from the Rotterdam School of
Management, a PhD with honors in Nuclear Chemistry and Neurobiology
and a PharmD with honors in Pharmacology from Paris University.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq:
SOPH) is a health care technology company dedicated to establishing
the practice of data-driven medicine as the standard of care and
for life sciences research. It is the creator of the SOPHiA DDM™
Platform, a cloud-based SaaS platform capable of analyzing data and
generating insights from complex multimodal data sets and different
diagnostic modalities. The SOPHiA DDM™ Platform and related
solutions, products and services are currently used by more than
790 hospital, laboratory, and biopharma institutions globally. For
more information, visit www.sophiagenetics.com, or connect on
Twitter, LinkedIn and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
Logo -
https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg